FDA approves neladalkib for ALK-positive lung cancer
-
By
-
Teraya Smith
-
November 18, 2026
-
2 min
By
Teraya Smith
November 18, 2026
A randomized cardiac surgery trial found noninferior bleeding control with refrigerated platelets, although reexploration rates and blood product requirements were higher.
October 16, 2026
The FDA approved a once-daily oral treatment for adults with symptomatic tenosynovial giant cell tumor.
by Teraya Smith
November 10, 2026
Median progression-free survival was 10 vs 5.5 months with giredestrant vs comparator therapy.
by Mouj Hijazi
November 17, 2026